Literature DB >> 6159309

Suppression and treatment of experimental allergic encephalitis in guinea-pigs with the bovine spinal cord protein (BSCP).

C F MacPherson.   

Abstract

Experimental allergic encephalitis (EAE) was suppressed in guinea-pigs that had been sensitized with 50 micrograms of bovine myelin basic protein (MyBP) in Freund's complete adjuvant (FCA) by daily injections of 500 micrograms of the bovine spinal cord protein (BSCP) in saline between day 8 (D 8) and D 23 after sensitization. Injections of 500 micrograms of bovine serum albumin in saline, or saline alone, did not suppress disease. Reversal of clinical disease was achieved with doses of 750 micrograms of BSCP in saline when treatment was begun within a day after the first sign of disease was observed. Six injections of 500 micrograms of BSCP in Freund's incomplete adjuvant (FIA) were required to suppress EAE whether BSCP-FIA injections were begun on D 0 or as late as D 8 when T cells sensitized to MyBP had invaded the central nervous system. When administration of BSCP-FIA was withheld until after disease onset, only three or four injections were needed to reverse clinical signs. BSCP appeared to be as effective quantitatively as MyBP in the suppression or treatment of disease. Because there is no cross-reaction between BSCP and MyBP at the antibody level, the present results raise the possibility that the suppressive activity of BSCP may be due to an amino acid sequence in BSCP and MyBP that is recognized only by T cells. When antigens were injected in FIA at 4 day intervals after sensitization, the onset of disease was delayed up to 5 days. Moreover, even bovine gamma-globulin appeared to have suppressive activity when injected three or four times in FIA. The findings suggest that assessments of the suppressive capacity of an antigen may be inaccurate if the antigen is injected in FIA frequently during the interval between sensitization and onset of disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6159309      PMCID: PMC1458063     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  ENCEPHALITOGEN-INDUCED INHIBITION OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS: PREVENTION, SUPPRESSION AND THERAPY.

Authors:  E C ALVORD; C M SHAW; S HRUBY; M W KIES
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  A histologic study of the early lesion in experimental allergic encephalomyelitis in the guinea pig and rabbit.

Authors:  B H WAKSMAN; R D ADAMS
Journal:  Am J Pathol       Date:  1962-08       Impact factor: 4.307

3.  Immunochemical and biochemical studies demonstrating the identity of a bovine spinal cord protein (SCP) and a basic protein of bovine peripheral myelin (BF).

Authors:  G E Deibler; B F Driscoll; M W Kies
Journal:  J Neurochem       Date:  1978-02       Impact factor: 5.372

4.  Studies on brain antigens. VI. Prevention of experimental allergic encephalomyelitis by a water-soluble spinal cord protein, 1 -SCP.

Authors:  C F MacPherson; S L Yo
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

5.  Protective action of the encephalitogen and other basic proteins in experimental allergic encephalomyelitis.

Authors:  H C Rauch; E R Einstein; J Csejtey; W J Davis
Journal:  Immunochemistry       Date:  1968-11

6.  Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids.

Authors:  C Webb; D Teitelbaum; A Herz; R Arnon; M Sela
Journal:  Immunochemistry       Date:  1976-04

7.  Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species.

Authors:  G E Deibler; R E Martenson; M W Kies
Journal:  Prep Biochem       Date:  1972

8.  T cell requirement for experimental allergic encephalomyelitis induction in the rat.

Authors:  L Ortiz-Ortiz; R M Nakamura; W O Weigle
Journal:  J Immunol       Date:  1976-08       Impact factor: 5.422

9.  Protection against experimental allergic encephalomyelitis with peptides derived from myelin basic protein: presence of intact encephalitogenic site is essential.

Authors:  B F Driscoll; M W Kies; E C Alvord
Journal:  J Immunol       Date:  1976-07       Impact factor: 5.422

10.  Experimental allergic encephalitis. Dissociation of cellular immunity to brain protein and disease production.

Authors:  L E Spitler; C M Von Muller; H H Fudenberg; E H Eylar
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

View more
  1 in total

1.  One-way humoral immune cross-reactivity between bovine spinal cord protein and bovine myelin basic protein.

Authors:  P Prokopchuk; B Ziola; I A Ramshaw; C F MacPherson
Journal:  Mol Immunol       Date:  1984-10       Impact factor: 4.407

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.